Skip to main content
OpenTrials
Completed

NCT Number: NCT02603705

Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain

The purpose of this study is to evaluate the safety and tolerability of Egalet-002 in opioid-experienced patients with moderate-to-severe chronic noncancer pain.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Site 334, Huntsville, Alabama, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Is a man or woman between 18 and 75 years of age.
  • Has a clinical history of moderate-to-severe chronic noncancer pain ≥6 months.
  • Has required opioid therapy for at least 14 days prior to Screening at a dose between 20 mg and 160 mg (inclusive) oxycodone/day (or opioid equivalent), and will, in the opinion of the investigator, continue to require opioid therapy (between 20 mg and 240 mg oxycodone/day, inclusive) for management of moderate-to-severe pain for the duration of the study.
  • Has pain either not adequately controlled on current opioid regimen, requires a change of opioid due to tolerability of current opioid regimen or in the opinion of the investigator, would benefit from changing opioid for another reason.
  • Has stable health, as determined by the investigator.
  • If female, the patient is currently not pregnant, not breast-feeding, nor attempting to become pregnant (for 30 days before screening through the duration of the study), or is of non-childbearing potential.
  • Other Criteria Apply

Exclusion criteria

  • Has cancer-related pain.
  • Is receiving >240 mg oxycodone daily (or opioid equivalent) within 30 days before Screening.
  • Has a history of attempted suicide.
  • Has used a spinal infusion pump within 6 months before Screening.
  • Has clinically unstable cardiac disease (including atrial fibrillation, symptomatic bradycardia, unstable congestive heart failure, or active myocardial ischemia) and/or respiratory disease (including chronic obstructive pulmonary disease or sleep apnea).
  • Has positive urine toxicity screen for drugs of abuse (with the exception of prescribed medications).
  • Has positive result for tetrahydrocannabinol (even if legally prescribed).
  • Has current (or history of within the last 12 months) drug dependence or substance abuse disorder according to Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, Text Revision criteria (excluding nicotine).
  • Other Criteria Apply

Treatment and study plan

Oxycodone extended-release

Drug

Primary outcomes

  1. Incidence of TEAEs during the Open-label Treatment Period, including those leading to treatment withdrawal, and/or abnormal physical examination findings, vital signs measurements, ECGs, and clinical laboratory test results, related to treatment

    Time frame: 1 year

Secondary outcomes

  1. Findings of the Brief Pain Inventory-Short Form (BPI-SF) during the Open-label Treatment Period

    Time frame: 1 year

Sponsors and collaborators

Lead sponsor

Egalet Ltd

Industry

Registry information

Official study title

An Open-label Phase 3 Trial to Evaluate the Safety and Tolerability of Egalet ADER Oxycodone Tablet, Egalet-002, in Patients With Moderate-to-Severe Chronic Noncancer Pain

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
Nov 13, 2015
Registry last updated
Mar 5, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.